KR101820084B1 - Solid formulation for oral administration containing tenofovir disoproxil and a process for the preparation thereof - Google Patents
Solid formulation for oral administration containing tenofovir disoproxil and a process for the preparation thereof Download PDFInfo
- Publication number
- KR101820084B1 KR101820084B1 KR1020160039649A KR20160039649A KR101820084B1 KR 101820084 B1 KR101820084 B1 KR 101820084B1 KR 1020160039649 A KR1020160039649 A KR 1020160039649A KR 20160039649 A KR20160039649 A KR 20160039649A KR 101820084 B1 KR101820084 B1 KR 101820084B1
- Authority
- KR
- South Korea
- Prior art keywords
- granules
- solid preparation
- wet
- binder
- preparation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2/00—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic
Abstract
One aspect of the present invention provides a pharmaceutical composition comprising tenofovir disoproxil or a pharmaceutically acceptable salt thereof as an active ingredient; And wet granules containing polyvinylpyrrolidone as a binder, and a process for producing the solid preparation.
Description
The present invention relates to an oral solid preparation containing tenofovir disoproxil and a preparation method thereof, and more particularly to a solid pharmaceutical preparation containing tenofovir disoproxil which is superior in terms of pharmaceutical efficacy, productivity and quality control, ≪ / RTI >
Tenofovir (Compound name: ({[(2R) -1-
(6-amino-9H-purin-9-yl) propan-2-yl] oxy} methyl) phosphonic acid) is a nucleotide analogue that is highly resistant to the human immunodeficiency virus HIV-1 virus and hepatitis B virus It is a nucleotide analogue reverse transcriptase inhibitor (NRTIs) that blocks the important enzyme, reverse transcriptase. Therefore, it inhibits the proliferation process of viruses such as HIV and HBV, It is effective in the treatment of hepatitis.
However, Tenofovir has a disadvantage of low bioavailability. An attempt to solve this problem is a tenofovir disoproxil (a compound of the following formula 1), which is a prodrug of Tenofovir.
[Chemical Formula 1]
Although tenofovir disoproxil has increased bioavailability, it is not stable and is used in the form of an acceptable salt of terfenoviridisoproxyl with added salt. Typically, tenofovir disoproxil fumarate (patent Document 1) is commercially available (VIREAD ? , Gilead Sciences, Inc). In addition, phosphates (Patent Document 2) and the like have been developed.
When administered as a gastrointestinal tract, tenofovir disesoproxyl or its salt is rapidly absorbed through the inner membrane of the body, and after the absorption, it changes into the form of tenofovir in the plasma and shows its efficacy. In terms of pharmacokinetics, the maximum plasma concentration ( Tmax ) of tenofovir disoproxil or its salt is fast within one hour, so it is rapidly disintegrated and eluted early on in the tablet form The desired therapeutic effect can be obtained by absorption into the body. In addition, in order to industrially mass produce oral solid preparations of tenofovir disoproxyl or salts thereof, excellent pharmaceutical properties in terms of productivity and quality control are required.
An aspect of the present invention is to provide an oral solid preparation containing tenofovir disoproxil which exhibits high initial elution of the active ingredient and is high in productivity and easy in quality control.
Another aspect of the present invention is to provide a method for producing an oral solid preparation containing tenofovir disoproxil, which exhibits high initial elution of the active ingredient and is high in productivity and easy in quality control.
One aspect of the present invention is
Tenofovir disoproxil or a pharmaceutically acceptable salt thereof as an active ingredient; And a wet granule comprising polyvinyl pyrrolidone as a binder.
Another aspect of the present invention is
A granulating step of preparing a wet granule comprising tenofovir disoproxil or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable additive;
A post-mixing step of preparing a mixture comprising the granulated wet granules and a pharmaceutically acceptable additive; And
Optionally, formulating the mixture,
Wherein polyvinylpyrrolidone is added as a binder in said granulating step.
There is provided a method of producing an oral solid preparation according to an aspect of the present invention.
The wet granules contained in the oral solid preparations according to one aspect of the present invention can have a high density and a low angle of repose because they contain polyvinyl pyrrolidone as a binder. Therefore, when the solid granules are formulated into solid formulations, Not only can a preparation be produced, but also a high initial dissolution rate can be obtained. Therefore, according to one aspect of the present invention, it is possible to produce an oral solid preparation containing tenofovir disoproxil, which is excellent in productivity in mass production, easy in quality control, and excellent in drug efficacy.
Hereinafter, the present invention will be described in more detail.
All technical terms used in the present invention are used in the sense that they are generally understood by those of ordinary skill in the relevant field of the present invention unless otherwise defined. In addition, preferred methods or samples are described in this specification, but similar or equivalent ones are also included in the scope of the present invention. The contents of all publications referred to in this specification are incorporated herein by reference in their entirety.
Since tenofoviridisoproxyl or its salt has a maximum blood concentration ( Tmax ) of less than 1 hour, it is rapidly disintegrated and eluted rapidly in the early stage after the administration of the solid agent, and the desired therapeutic effect can be obtained . In order to industrially produce a solid preparation for oral use of tenofovir disoproxil or a salt thereof, the productivity of the solid preparation should be excellent, and the flowability of the granules used for the preparation of the solid preparation should be excellent. Generally, in order to obtain a rapid early release of a solid preparation, it is desirable to make the granules bulk (low density). When the density is low, a tableting trouble such as capping occurs during tableting and the mass deviation of the tableted tablet becomes large There is a concern. As a result of the study, it was found that wet granules have higher density and lower angles of repose than dry gel granules, and thus productivity is excellent. When polyvinyl pyrrolidone is used as a binder in wet granules, The elution was equal to or more than that of the control preparation, and thus it was found to have a superior drug efficacy. Accordingly, the present inventors have developed a tenofovir disoproxil solid preparation in which tenofovir disoproxil is prepared as a wet granule and the initial dissolution is increased. As a result, a solid preparation having productivity and superior drug efficacy even in mass production is provided It became possible.
The present invention, in one aspect,
Tenofovir disoproxil or a pharmaceutically acceptable salt thereof as an active ingredient; And a wet granule comprising polyvinyl pyrrolidone as a binder.
The pharmaceutically acceptable salt includes an acid addition salt, and the acid addition salt includes an inorganic acid salt or an organic acid salt.
The inorganic acid salt includes, but is not limited to, hydrochloride, phosphate, sulfate or disulfate. The organic acid salt may be at least one selected from the group consisting of fatty acid salts such as acetate, dichloroacetate, adipate, alginate, ascorbate, camphorate, caprate, caproate, caprylate, cyclamate, galactarate, glucoside, glucuronate , Glutamate, oxoglutarate, lactobionate, thiocyanate, malonate, uronate, propionate, decanoate, caprylate, acrylate, formate, isobutyrate, heptanoate, But are not limited to, lactose, malonate, succinate, suberate, sebacate, maleate, orotate, myristate, butyne-1,4-dioate, hexyne-1,6-dioate, citrate, lactate, Butyrate, glycolate, maleate, tartrate; Methanesulfonate, propanesulfonate, camposulfonate, camsylate, eddylate, escitalate, isethionate, which are aliphatic sulfone organic acid salts; Aromatic organic acid salts such as benzoate, chlorobenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, phthalate, terephthalate, phenylacetate, phenylpropionate, phenylbutyrate, mandelate, salicylate , Para-aminosalicylate, tannate, cinnamate; But are not limited to, aromatic sulfonic organic acid salts such as benzene sulfonate, toluene sulfonate, xylene sulfonate, naphthalene-1-sulfonate, or naphthalene-2-sulfonate.
In one embodiment, the pharmaceutically acceptable salt of tenofovir disoproxyl can be a phosphate, orotate, fumarate or succinate salt.
In one embodiment, the pharmaceutically acceptable salt of the tenofovir disoproxyl is a phosphate.
As a result, the wet granules of Tenofovir disoproxil showed higher density and smaller angle of repose than the dry granules, and it was shown that high productivity and quality control were easy when manufacturing the granules. However, The formulation showed a relatively low initial dissolution rate as compared to the solid preparation tableted with dry granules. In addition, wet granules had a smaller angle of repose than dry granules, but did not reach the angle of repose angle of 35-40 degrees (see Test Examples 1 and 2) required for productivity. When the wet granules containing tenofovir disoproxil are used as binders and various binders are used, the range of angle of repose required for securing the productivity is reached to 35-40 degrees. However, when the tablets are manufactured by tableting, the hydroxypropylcellulose ( HPC) or carboxymethylcellulose sodium (CMC-Na) as a binder did not exhibit an early dissolution rate as good as the control preparation. On the contrary, when polyvinylpyrrolidone was used as a binder, the initial dissolution rate equal to or higher than that of the control preparation was obtained (see Test Examples 3 to 6). On the other hand, adding the known disintegrant to the preparation of wet granules generally used for increasing the dissolution rate of the active ingredient did not reach the initial dissolution rate of the control preparation (see Test Examples 7 and 8). Therefore, it has been confirmed that the wet granule produced by using polyvinyl pyrrolidone as the binder can produce an oral solid preparation having an effective early dissolution rate while ensuring high productivity and ease of quality control.
As used herein, the term " early dissolution rate "means a dissolution rate within about 1 hour, more specifically, a dissolution rate within about 30 minutes after oral administration. In one embodiment, the initial release rate can be determined by dissolving the solid formulation in a 0.1 N hydrochloric acid solution at a paddle rotation rate of about 50 rpm according to the dissolution method 2 of the Korean Pharmacopoeia.
The polyvinylpyrrolidone may be any polyvinylpyrrolidone used as a binder in the pharmaceutical field. The polyvinyl pyrrolidone may be polyvinyl pyrrolidone having a molecular weight of about 30,000 to 100,000.
In one embodiment, the polyvinylpyrrolidone is polyvinylpyrrolidone having a molecular weight of about 30,000 to 50,000.
The content of the polyvinylpyrrolidone in the solid preparation can be appropriately selected by a person skilled in the art, and may vary depending on the molecular weight of the polyvinylpyrrolidone. The polyvinylpyrrolidone may be contained in the solid preparation in an amount of, for example, about 1 to 10% by weight, and more specifically about 1 to 5% by weight.
In one embodiment, the polyvinylpyrrolidone has a molecular weight of from 30,000 to less than 50,000, and may be included in an amount of about 1 to 5% by weight based on the total amount of the solid preparation.
In one embodiment, the oral solid preparation is particularly preferred for high volume production. The term "mass production" as used herein means an amount of the granulated product produced by the dry granulation method when granulating cannabisidiclofosil is less than that produced by the wet granulation method, , Conditions of the granule production method, and the like. In one embodiment, the mass production means 20 kg or more per granule per batch. In mass production, it is produced by wet granulation, so that the granular density is increased by the dry granulation method, the mass deviation is lowered due to the reduction of angle of repose and the flowability is improved, so that the quality control and productivity are excellent and polyvinyl pyrrolidone It is possible to secure an excellent early dissolution.
In the present specification, the term "solid preparation" means a preparation which is formed by molding or spraying the drug into a certain shape. The oral solid preparations may be any oral solid preparations which may be prepared as wet granules or may contain wet granules, for example pellets, capsules, tablets (including single layer tablets, bi-layer tablets, Dry syrups, granules, and the like, but the present invention is not limited thereto. More specifically, the oral solid combination preparation may be in the form of a capsule, a single-layer tablet or a two-layer tablet. When the oral solid preparation for oral use is a capsule, the capsule may be in the form of granules or tablets. In one embodiment, the oral solid preparation is a tablet.
The oral solid preparation may further comprise at least one pharmaceutically acceptable additive in addition to the active ingredient and the binder as polyvinyl pyrrolidone. Specifically, the pharmaceutically acceptable additive may further comprise at least one substance selected from the group consisting of a diluent, a binder, a disintegrant, a lubricant, and any combination thereof.
The diluent may be selected from the group consisting of mannitol, lactose, starch, microcrystalline cellulose, ruddy press, calcium dihydrogenphosphate, and any combination thereof, but is not limited thereto. The diluent may be included in an amount of about 1 to 99% by weight, preferably about 20 to 80% by weight, based on the total weight of the solid preparation.
The binder may be an optional additional binder in addition to the polyvinylpyrrolidone. For example, it may be selected from the group consisting of hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylalcohol, carboxymethylcellulose sodium, and any combination thereof, but is not limited thereto. The binder may be included with the polyvinyl pyrrolidone in an amount of about 1 to 10% by weight, preferably about 1 to 5% by weight, based on the total weight of the solid formulation.
The disintegrant may be selected from the group consisting of pregelatinized starch, croscarmellose sodium, crospovidone, sodium starch glycolate, and any combination thereof, but is not limited thereto. The disintegrant may be used in an amount of about 0.5 to 50% by weight, preferably about 1 to 30% by weight, based on the total weight of the solid preparation.
The lubricant may be selected from the group consisting of stearic acid, metal salts of stearic acid (e.g., calcium stearate, magnesium stearate), talc, colloidal silica, sucrose fatty acid ester, hydrogenated vegetable oil, wax, glyceryl fatty acid esters, glycerol dibehenate, And any combination thereof. However, the present invention is not limited thereto. The lubricant may be included in an amount of 0.3 to 10% by weight, preferably 0.5 to 5% by weight, based on the total weight of the solid preparation.
The wet granules can be prepared by any wet granulation method. In one embodiment, the wet granulate may be one produced by a fluidized bed granulator.
In one embodiment, the solid preparation comprises tenofovir disoproxil or a pharmaceutically acceptable salt thereof as an active ingredient; And a wet granule comprising polyvinylpyrrolidone as a binder and produced by a fluidized bed granulator.
In one embodiment, the oral solid preparation may contain about 0.1-500 mg of the active ingredient per unit dosage form of tenofovir disoproxyl or a pharmaceutically acceptable salt thereof as the free base, and the total weight of the solid preparation By weight, based on the total weight of the composition, of 0.5 to 60% by weight, specifically 1 to 55% by weight.
In one embodiment, the solid formulation is prepared by dissolving the solid preparation in a solution of about 0.1 N hydrochloric acid at a paddle rotation rate of about 50 rpm according to dissolution method 2 of Pharmacopoeia Of about 95% or more of the dissolution rate of tenofovir disoproxil.
The oral solid preparation can be administered to a mammal, including a human, having any indication of tenofovir disoproxil or a pharmaceutically acceptable salt thereof. Thus, the oral solid preparation can be used for the treatment of HIV-1 or chronic hepatitis B, but is not limited thereto.
According to another aspect of the present invention,
A granulating step of preparing a wet granule comprising tenofovir disoproxil or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable additive;
A post-mixing step of preparing a mixture comprising the granulated wet granules and a pharmaceutically acceptable additive; And
Optionally, formulating the mixture,
Wherein the granulating step comprises adding polyvinylpyrrolidone as a binder in the granulating step, in accordance with an aspect of the present invention.
The details of the method for producing the oral solid preparation according to this aspect can be applied as the description of the oral solid preparation according to one aspect of the present invention as it is.
The granulation step for producing the wet granules may be manufactured according to any wet granule manufacturing method known in the art.
The wet granulation method may be carried out by granulating a mixture containing tenofovir disoproxil or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable additive into a binding liquid, and drying the resultant. As the binder, polyvinylpyrrolidone may be added in addition to both of the mixture, the bonding liquid, or the mixture and the bonding liquid.
The pharmaceutically acceptable additives used in the granulation step may be selected from diluents, binders, disintegrants, and any combination thereof.
The solvent for preparing the binding solution may be water, ethanol, isopropanol, acetone, or any combination thereof. In addition to the binder, the binding liquid may be prepared by adding to the solvent additional additives commonly used in the pharmaceutical field, for example, a surfactant, a buffer, or a combination thereof. According to one embodiment, the binding liquid is an aqueous solution containing polyvinylpyrrolidone as a binder.
The drying process may be carried out by air drying, fluid bed drying, oven drying or microwave drying at a temperature not exceeding about 60 캜, preferably not exceeding about 50 캜, in view of the stability of the active ingredient .
In the post-mixing step of mixing the wet granules with the pharmaceutical additive, the additive may be a disintegrant and / or a lubricant. In one embodiment, the disintegrant is crospovidone. In one embodiment, the lubricant is a sucrose fatty acid ester.
The formulation may be carried out according to any method known in the art for the formulation of a solid preparation using granules and may be carried out in the form of tablets, capsules, pellets, or dry syrups, The method can be carried out according to the method. In one embodiment, the step of formulating is a step of preparing the tablet.
In one embodiment, the method of making the solid formulation comprises a process for producing granules in high volume production of about 20 kg or more per granule per batch. According to the manufacturing method according to one embodiment, compared to the dry granulation method and the wet granulation method which does not use polyvinyl pyrrolidone, the produced granules have a low angle of repose and a high density, It is possible to produce an effective pharmaceutical composition containing Tenofovir disoproxil because the productivity is good and the mass deviation is low so that the quality control is easy and the early dissolution rate of the active ingredient is high.
The granulation step may be carried out in any wet granulation process known in the art, for example, using a high speed mixer or fluidized bed granulator. In one embodiment, the granulation step may be granulated using a fluid bed granulator. It can be more advantageous in terms of the initial dissolution rate when it is produced by a fluidized bed granulator.
Hereinafter, the present invention will be described in detail based on the following examples. However, the following examples are intended to illustrate the present invention, but the scope of the present invention is not limited thereto.
Production Examples 1-1 to 1-3: Preparation of granules and tablets according to the granule manufacturing method
[Table 1] Preparation of granules according to granule manufacturing method
The granules and tablets were prepared according to the above Table 1, and the specific manufacturing method was as follows.
≪ Purification after dry granule production >
As shown in Table 1 above, tenofovir disoproxil phosphate was mixed with microcrystalline cellulose, lactose and pregelatinized starch by the ingredients and contents described in 'Additive type and amount'. The resulting mixture was sieved through a 20-mesh sieve, and then placed in a polyethylene bag for mixing for 15 minutes. Then, 10 mg of crospovidone and 2 mg of sucrose fatty acid ester were mixed. Thereafter, a part of the tablets were used for tablets.
<Purification after manufacturing wet granule with high speed mixer>
Tenofovir disoproxil phosphate was mixed with microcrystalline cellulose, lactose and pregelatinized starch by the ingredients and content described in Table 1, 'Additive types and amounts'. This was dried with a combination of purified water and a binding liquid (combined conditions: Agitator speed: 150 rpm, Agitator pressure: 1.6 A, Chopper speed: 3000 rpm), and sieved with about 20 mesh sieve to prepare wet granules of tepofovir disoproxyl phosphate. The wet granules are then mixed with 10 mg of crospovidone and 2 mg of sucrose fatty acid ester to produce the final granulate. Thereafter, a part of the tablets were used for tablets.
≪ Purification after preparation of wet granules with fluidized bed granulator >
Tenofovir disoproxil phosphate was mixed with microcrystalline cellulose, lactose and pregelatinized starch by the ingredients and content described in Table 1, 'Additive types and amounts'. The mixture was poured into a fluidized bed granulator, and then the machine was operated at an inlet temperature of 50 ° C. and a spray pressure of 0.8 bar. Spray was sprayed at a rate of 10 rpm to inject the bonding solution (purified water). During the injection of the binding liquid, the granules were assembled under the same initial conditions, and then the temperature of the Inlet was lowered by 45 ° C. to dryness. After drying, the wet granules were prepared by sieving with about 20 mesh sieve. The wet granules were then mixed with 10 mg of crospovidone and 2 mg of sucrose fatty acid ester to prepare final granules. Thereafter, a part of the tablets were used for tablets.
Production Examples 2 to 4: Preparation of wet granules and tablets according to binder type
[Table 2] Preparation of wet granules according to binder type
Tablets were prepared according to the above Table 2, and the specific production method was as follows.
Tenofovir disoproxil phosphate was mixed together with microcrystalline cellulose, lactose and pregelatinized starch by the ingredients and content described in Table 2, 'Additive types and amounts'. The mixture was injected into a fluidized bed granulator, and the machine was operated at an inlet temperature of 50 ° C. and a spray pressure of 0.8 bar. The spray was sprayed at a speed of 10 rpm to obtain a binding solution (concentration of binding solution was about 5% w / w And purified water was added to each of the corresponding binders to prepare a binding solution). During the injection of the binding liquid, the granules were assembled under the same initial conditions, and then the temperature of the Inlet was lowered by 45 ° C. to dryness. After drying, the wet granules were prepared by sieving with about 20 mesh sieve. The wet granules were then mixed with 10 mg of crospovidone and 2 mg of sucrose fatty acid ester to prepare final granules. Thereafter, a part of the tablets were used for tablets.
Examples 1 to 4: Preparation of wet granules and tablets containing polyvinylpyrrolidone
[Table 3] Preparation of wet granules and tablets containing polyvinylpyrrolidone
Tablets were prepared according to Table 3, and the specific preparation method was as follows.
As shown in Table 3 above, tenofovir disoproxil phosphate was mixed with microcrystalline cellulose, lactose and pregelatinized starch by the ingredients and contents described in 'Additive type and amount'. The mixture was injected into a fluidized bed granulator, and the machine was operated at an inlet temperature of 50 ° C. and a spray pressure of 0.8 bar. The spray was sprayed at a speed of 10 rpm to obtain a binding solution (concentration of binding solution was about 5% w / w And purified water was added to each of the corresponding binders to prepare a binding solution). Granulation equipment and process parameter setting values were the same as those of Production Examples 2 to 4 above. During the injection of the binding solution, the granules were assembled under the same initial conditions, and the temperature of the Inlet was lowered to 45 ° C. during drying. The dried granules were dried and then sieved with a 20 mesh sieve to prepare wet granules. The wet granules were then mixed with 10 mg of crospovidone and 2 mg of sucrose fatty acid ester to prepare final granules. Thereafter, a part of the tablets were used for tablets.
Example 5: Preparation of wet granules and tablets according to the amount of disintegrant injected into post-mix
[Table 4] Preparation of granules according to the amount of disintegrant to be added in post-mixing
Tablets were prepared according to the above Table 4, and the specific preparation method was as follows.
As shown in Table 4 above, tenofovir disoproxil phosphate was mixed with microcrystalline cellulose, lactose and pregelatinized starch by the ingredients and contents described in 'Additive type and amount'. The mixture was injected into a fluidized bed granulator and sprayed at a rate of 10 rpm by operating the machine at an inlet temperature of 50 ° C. and a spray pressure of 0.8 bar to prepare a binding solution (2 mg of polyvinylpyrrolidone with a concentration of about 5 w / w% to prepare a binding solution). Granulation equipment and process parameter setting values were the same as those of Production Examples 2 to 4 above. During the injection of the binding liquid, the granules were assembled under the same initial conditions, and then the temperature of the Inlet was lowered by 45 ° C. to dryness. After drying, the wet granules were prepared by sieving with about 20 mesh sieve. Thereafter, the wet granules were mixed with 2 mg of sucrose fatty acid ester corresponding to the amount of crospovidone, to prepare final granules. Thereafter, a part of the tablets were used for tablets.
Test Example 1: Measurement of density and repose angle of granules according to granulation method
For comparison of physical properties of the three granules of Production Examples 1-1 to 1-3, density and angle of repose were measured and the results are shown in Table 5 below.
[Table 5]
According to the results shown in Table 5, the wet granules have smaller angle of repose than the dry granules, showing excellent fluidity and high density. Therefore, it was shown that the process for filling the wet granules with the tablet compared to the dry granules can produce tablets having excellent productivity and low mass deviation when filled into the feeder. However, it did not reach the range of angle of repose angle of 35-40 degrees to obtain excellent productivity in tablet production.
Test Example 2: Evaluation of dissolution rate of tablets tableted with granules according to granule preparation method
In order to evaluate the dissolution profiles of the tablets prepared in Production Examples 1-1 to 1-3, the following tests were carried out. The same dissolution test conditions as the US FDA recommended dissolution conditions were made.
≪ Dissolution test conditions >
1) Elution method: Elution of Korean Pharmacopoeia Method 2 (paddle method)
2) Elution: 0.1 N hydrochloric acid solution, 900 ml
3) Elution temperature: 37.5 DEG C
4) Paddle speed: 50 rpm
5) Number of tests: 6
6) Sampling time: 10 minutes and 30 minutes
≪ Specimen analysis condition >
Detector: ultraviolet absorption spectrophotometer (measuring wavelength: 260 nm)
Cell length: 1 cm
The dissolution test results of tablets prepared in Production Examples 1-1 to 1-3 are shown in Table 6 below.
[Table 6]
According to the results of the dissolution test, the dissolution rate similar to that of the control preparation could be obtained in the tablets made from the dry granules. However, as shown in Table 5, since the granule density is somewhat low, it is possible to cause the mass deviation of the tablets in mass production, The flowability is low and the productivity is low.
The wet granules have a lower angle of repose than the dry granules, but they do not reach the range of angle of repose for obtaining excellent productivity in tablet production. In addition, the tablets made from wet granules had a higher initial dissolution rate than the tablets prepared with dry granules, and the tablets prepared with the granules of the fluidized bed granulator had a higher initial dissolution rate than the tablets made with the high speed mixer , But it did not reach the dissolution rate of 10 minutes of the control preparation.
Test Example 3: Measurement of physical properties of granules prepared according to binder type and amount
For comparison of the physical properties of the granules of Production Examples 2 to 4, density and angle of repose were measured, and the results are shown in Table 7 below.
[Table 7]
Test Example 4: Evaluation of dissolution rate for tablets prepared according to binder type and amount
In order to evaluate the dissolution profiles of the nine tablets prepared in Preparative Examples 2 to 4, the dissolution test was carried out according to the same test method as in Test Example 2 above.
The results of the dissolution test of tablets prepared in Production Examples 2 to 4 are shown in Table 8 below.
[Table 8]
According to the density and angle-of-inclination test results of Table 7, when the wet granules were produced using the three binders used in Production Examples 2 to 4, the granules had a high density and the mass deviation during the production of the tablets was expected to be low. 35-40 degrees of angle of repose showed high flowability and it was found to be advantageous in productivity. It is believed that this is because the bonding strength of the binder is excellent and the granules having a relatively high density are produced, thereby exhibiting excellent flowability.
However, according to the results of the dissolution test of Table 8, it was shown that all of the binders used in Production Examples 2 to 4 lowered the active ingredient elution of the tablets. In all of the nine tablets, the 10-minute dissolution rate and the 30-minute dissolution rate And the results were not significantly different from the control preparation (10 minutes elution rate: about 90% or more, 30 minutes elution rate: about 95 or more).
Test Example 5: Measurement of physical properties of wet granules containing polyvinylpyrrolidone
Density and angle of repose were measured for comparing the physical properties of the 12 granules prepared in Example 1-4, and the results are shown in Table 9 below.
[Table 9]
Test Example 6: Polyvinylpyrrolidone Wet granules containing Tender Evaluation of dissolution rate of tablets
In order to evaluate the dissolution profiles of the twelve tablets prepared in Examples 1 to 4, a dissolution test was carried out according to the same test method as in Test Example 2 above.
The results of the dissolution test of the tablets prepared in Examples 1 to 4 are shown in Table 10 below.
[Table 10]
According to the results of the density and angle-of-inclination test shown in Table 9, when the wet granules were produced using the polyvinyl pyrrolidone having various molecular weights as used in Example 1-4, the granules had a high density, And the flow angle is about 35-40 degrees and the flowability is high, so that the productivity of the solid preparation is advantageous.
According to the dissolution test results of Table 10, in Examples 1 and 2 using polyvinylpyrrolidone as a binder different from Production Examples 2 to 4 using other binders, the dissolution rate of 10 minutes or more and the dissolution rate of 30 minutes .
Particularly, polyvinylpyrrolidone having a molecular weight of about 30,000 to 50,000 (Example 1-2) had a dissolution rate of 10 minutes or more and a dissolution rate of 30 minutes, which is equivalent to or higher than that of the control preparation, whereas a polyvinylpyrrolidone having a molecular weight of about 400,000 or more The money did not reach the 10 minute dissolution rate and the 30 minute dissolution rate of the control preparation.
In addition, in the case of using polyvinylpyrrolidone having a molecular weight of about 30,000 to 50,000 (Example 1-2), it was confirmed that the amount of polyvinylpyrrolidine that can exhibit a dissolution rate of 10 minutes or more and a dissolution rate of 30 minutes The results are as follows. In the case of Example 1 using a polyvinylpyrrolidone having a molecular weight of about 30,000, the dissolution rate (10 minutes dissolution rate: about 90% or more, 30 minutes In the case of Example 2 using polyvinylpyrrolidone having a molecular weight of about 50,000, about 1 to 3% by weight of the total weight of the tablet was used, and the dissolution rate was equal to or higher than that of the control preparation .
Test Example 7: Measurement of physical properties of wet granules according to the amount of disintegrant to be added in post-mixing
For comparison of the physical properties of the four granules prepared in Example 5, the density and the angle of repose were measured and the results are shown in Table 11 below.
[Table 11]
Test Example 8 : After mixing Be injected into Disintegration The wet granulation according to the amount Tender Evaluation of dissolution rate of tablets
In order to evaluate the dissolution profile of the four tablets prepared in Example 5, a dissolution test was carried out according to the same test method as in Test Example 2 above.
The results of the dissolution test of tablets prepared in Example 5 are shown in Table 12 below.
[Table 12]
(2 mg of polyvinylpyrrolidone having an MW of 400,000 as a binder) was prepared in the same manner as in Example 3-1. The results of the test according to the amount of the disintegrant (crospovidone) And Table 12 show that in Example 5, as the amount of disintegrant added to the post-mix increases, the density of the granules becomes smaller than that of Example 3-1 (increase in differentials) Thereby causing a side effect of lowering the productivity.
From the aspect of the dissolution rate, it was confirmed that the dissolution rate of Example 5 was slightly less than the dissolution rate of 10 minutes compared with Example 3-1, and all of Example 5 did not reach the dissolution rate of the control preparation. Thus, it has generally been found that increasing the amount of disintegrant used to increase the elution of the active ingredient does not significantly improve the dissolution rate of tenofovir disoproxil. Thus, the choice of binder was more important than the disintegrant for improving the dissolution rate of the tablet formulation containing tenofovir disoproxil wet granules.
The present invention has been described with reference to the preferred embodiments. It will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention as defined by the appended claims. Therefore, the above-described embodiments should be considered in an illustrative rather than a restrictive sense. The scope of the present invention is defined by the appended claims rather than by the foregoing description, and all differences within the scope of equivalents thereof should be construed as being included in the present invention.
Claims (13)
A post-mixing step of preparing a mixture comprising the granulated wet granules and a pharmaceutically acceptable additive,
Wherein polyvinylpyrrolidone having a molecular weight of 30,000 to 50,000 is added as a binder in an amount of 1 to 5% by weight based on the total amount of the solid preparation in the granulating step.
11. A method for preparing a solid preparation for oral use according to any one of claims 1 to 9.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020160039649A KR101820084B1 (en) | 2016-03-31 | 2016-03-31 | Solid formulation for oral administration containing tenofovir disoproxil and a process for the preparation thereof |
| PCT/KR2017/001349 WO2017171222A1 (en) | 2016-03-31 | 2017-02-08 | Solid preparation for oral administration containing tenofovir disoproxil and method for preparing same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020160039649A KR101820084B1 (en) | 2016-03-31 | 2016-03-31 | Solid formulation for oral administration containing tenofovir disoproxil and a process for the preparation thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20170112519A KR20170112519A (en) | 2017-10-12 |
| KR101820084B1 true KR101820084B1 (en) | 2018-01-18 |
Family
ID=59965937
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020160039649A KR101820084B1 (en) | 2016-03-31 | 2016-03-31 | Solid formulation for oral administration containing tenofovir disoproxil and a process for the preparation thereof |
Country Status (2)
| Country | Link |
|---|---|
| KR (1) | KR101820084B1 (en) |
| WO (1) | WO2017171222A1 (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015085976A1 (en) * | 2013-12-09 | 2015-06-18 | Zentiva, K.S. | A stable pharmaceutical composition containing tenofovir disoproxil fumarate |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009106954A1 (en) * | 2008-02-27 | 2009-09-03 | Aurobindo Pharma Limited | Stable dosage forms of lamivudine and tenofovir |
| AU2015245217A1 (en) * | 2014-04-08 | 2016-10-13 | Teva Pharmaceutical Industries Ltd. | Unit dosage form comprising Emtricitabine, Tenofovir, Darunavir and Ritonavir |
| KR20160003532A (en) * | 2014-07-01 | 2016-01-11 | 한미약품 주식회사 | Tenofovir disoproxil phosphate, and pharmaceutical composition comprising non-metalic salt disintegrant and non-metalic salt lubricant |
-
2016
- 2016-03-31 KR KR1020160039649A patent/KR101820084B1/en active IP Right Grant
-
2017
- 2017-02-08 WO PCT/KR2017/001349 patent/WO2017171222A1/en active Application Filing
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015085976A1 (en) * | 2013-12-09 | 2015-06-18 | Zentiva, K.S. | A stable pharmaceutical composition containing tenofovir disoproxil fumarate |
Non-Patent Citations (1)
| Title |
|---|
| Chemical and Pharmaceutical Bulletin, 42(10), 1994, pp.2121-2125* |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20170112519A (en) | 2017-10-12 |
| WO2017171222A1 (en) | 2017-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI597073B (en) | Solid pharmaceutical compositions and processes for their production | |
| KR102317664B1 (en) | Solid formulation for for oral administration containing irinotecan and a process for the preparation thereof | |
| EP3437646A1 (en) | Oral preparation having exceptional elutability | |
| JP5103173B2 (en) | Method for preventing decomposition of dihydropyridine compounds | |
| EP2799072A1 (en) | Solid pharmaceutical composition comprising an antibiotic from the quinolone family and method for the production thereof | |
| KR100522239B1 (en) | Compositions for controlled release acetaminophen dosage forms | |
| KR101834559B1 (en) | Solid composite formulation for oral administration comprising ezetimibe and rosuvastatin | |
| CA3079567A1 (en) | Lenalidomide immediate release formulations | |
| CN106511291A (en) | Acotiamide hydrochloride controlled release tablet and preparation method thereof | |
| KR101820084B1 (en) | Solid formulation for oral administration containing tenofovir disoproxil and a process for the preparation thereof | |
| CN106994121B (en) | A pharmaceutical composition for treating cancer | |
| CN107072954B (en) | Pharmaceutical composition for oral administration comprising lobemidone | |
| CN107865826B (en) | Solid dispersion of E-configuration benzamide compound | |
| JP2020518611A (en) | Compositions with improved water solubility and bioavailability | |
| JP7336528B2 (en) | Process for producing pharmaceutical compositions containing nefopam and acetaminophen, and pharmaceutical compositions obtained thereby | |
| KR102206535B1 (en) | Oral composite tablet comprising ezetimibe and rosuvastatin | |
| KR20170095525A (en) | Process for preparing telmisartan-containing tablets | |
| CN111939134A (en) | Antiviral medicine composition | |
| JP6739289B2 (en) | Process for producing pharmaceutical tablet containing gefitinib as active ingredient | |
| KR102363727B1 (en) | Composition for preparing solid formulation containing pranlukast having enhanced bioavailability and production method thereof | |
| KR101944085B1 (en) | Solid oral dosage form containing valsartan, and preparation method therefor | |
| KR20160082170A (en) | An oral solid formulation containing rivaroxaban | |
| KR101048487B1 (en) | Trimebutin Maleic Acid | |
| KR20170003063A (en) | Solid formulation for oral administration containing tenofovir disoproxil and a process for the preparation thereof | |
| TWI353836B (en) | Process for producing pharmaceutical preparation c |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| AMND | Amendment | ||
| E601 | Decision to refuse application | ||
| AMND | Amendment | ||
| X701 | Decision to grant (after re-examination) |